503 related articles for article (PubMed ID: 14581422)
1. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
2. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
3. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
6. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
7. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.
Kang DE; White RL; Zuger JH; Sasser HC; Teigland CM
J Urol; 2004 May; 171(5):1806-9. PubMed ID: 15076281
[TBL] [Abstract][Full Text] [Related]
10. F-18 FDG PET in detecting renal cell carcinoma.
Ak I; Can C
Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
[TBL] [Abstract][Full Text] [Related]
11. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
12. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
13. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG PET-CT in recurrent renal cell carcinoma.
Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
[TBL] [Abstract][Full Text] [Related]
16. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography--a preliminary report.
Chang CH; Shiau YC; Shen YY; Kao A; Lin CC; Lee CC
Urol Int; 2003; 71(3):306-9. PubMed ID: 14512653
[TBL] [Abstract][Full Text] [Related]
17. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
18. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
20. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography.
Chang JT; Chan SC; Yen TC; Liao CT; Lin CY; Lin KJ; Chen IH; Wang HM; Chang YC; Chen TM; Kang CJ; Ng SH
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):501-7. PubMed ID: 15890593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]